Search or
𝛼SK
𝛼SKbullish
Samsung C&T (028260 KS/Buy)Biologics Business Accounts for 73% of Operating Profit
For 3Q25, Samsung C&T reported consolidated revenue of W10.2tr (-1.5% YoY) and operating profit of W993.4bn (+35% YoY), with the latter beating the consensus (W791.9bn) by 25%.
What is covered in the Full Insight:
- Introduction
- Earnings Summary
- Biologics Business Performance
- E&C Segment Outlook
- Conclusion and Analyst Recommendations
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 16-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
x